SCHEMBL6132610

SCHEMBL6132610

COCCCCCCOC1CCN(C(=O)O)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LSS P48449 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NAMPT P43490 1/20 0.38
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 1/20 0.34
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
GAA P10253 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
LIPC P11150 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
BCHE P06276 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5270128 0.83 LIPC (0.42) LSSALDH1A1NAMPTKMT2ALIPC
SCHEMBL13349907 0.83 LIPC (0.40) LSSALDH1A1NAMPTTSHRF2
SCHEMBL21997272 0.82 DPP7 (0.39) LSSNAMPTF2PRSS1BCHE
SCHEMBL27517067 0.82 NAMPT (0.41) LSSNAMPTF2PRSS1ITGB3
SCHEMBL9030287 0.82 KMT2A (0.39) LSSNAMPTKMT2ACYP3A4EPHX2
SCHEMBL30267164 0.81 NAMPT (0.40) LSSALDH1A1NAMPTF2PRSS1
SCHEMBL6132348 0.81 HPGD (0.46) ALDH1A1
SCHEMBL9030276 0.81 LSS (0.37) LSSALDH1A1NAMPTTSHRKMT2A
SCHEMBL6134492 0.80 TAAR1 (0.42) LSSNAMPTF2PRSS1GAA
SCHEMBL9030108 0.79 NPC1 (0.38) LSSALDH1A1NAMPTTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 LSS 251/4885ALDH1A1 4718/4885NAMPT 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.